SUBSCRIBE
Login
Back to all insights

Unlocking Flexibility: FDA’s 2025 Guidance on pH Adjuster Waivers for Complex Generics

Looking For Service?

Introduction

The guidance addresses how generic-drug applicants (via an Abbreviated New Drug Application, ANDA) may request a waiver under 21 CFR 314.99(b) of the requirement in 21 CFR 314.94(a)(9)(iii) and (iv) that inactive ingredients (specifically pH adjusters) in a generic product be qualitatively (Q1) and quantitatively (Q2) the same as the Reference Listed Drug (RLD), when the generic is intended for parenteral (injectable), ophthalmic (eye) or otic (ear) use. U.S. Food and Drug Administration+2U.S. Food and Drug Administration+2
The document is guidance only (non-binding) and reflects the FDA’s current thinking. U.S. Food and Drug Administration+1
The guidance is applicable only to pH adjusters (an inactive ingredient) in the specified routes; it does not apply to other inactive ingredients or other dosage forms. U.S. Food and Drug Administration+1

Background and Regulatory Context

Statutory/Regulatory Basis

  • The ANDA pathway (under the Hatch-Waxman Amendments) allows a generic applicant to reference an RLD and must show, among other things, same active ingredient, dosage form, route, strength, conditions of use, and bioequivalence. U.S. Food and Drug Administration
  • While the law (21 U.S.C. 355(j) and related) does not require that a generic have the identical inactive ingredients as the RLD, a generic may not be approved if the inactive ingredients are unsafe for the proposed conditions of use. U.S. Food and Drug Administration
  • Regulations such as 21 CFR 314.94(a)(9)(iii) and (iv) and 21 CFR 314.127(a)(8)(ii)(B)/(C) impose stricter requirements for products intended for parenteral, ophthalmic or otic use: generally, the same inactive ingredients in the same concentration as the RLD unless otherwise justified. U.S. Food and Drug Administration+1

Waiver Provision

  • Under 21 CFR 314.99(b), an ANDA applicant may request a waiver to a requirement under §§ 314.92 through 314.99 if:
    1. compliance with the requirement is unnecessary for FDA to evaluate the application or cannot be achieved; or
    2. an alternative submission satisfies the requirement; or
    3. other information justifies the waiver. U.S. Food and Drug Administration+1
  • Even if a waiver is granted, the generic product must still meet all statutory and regulatory standards for approval (safety, efficacy, quality). U.S. Food and Drug Administration

When a Waiver for pH Adjusters May Be Appropriate

Role of pH Adjusters

  • A pH adjuster (commonly an acid or base) is used to adjust the equilibrium concentration of hydronium ions (H₃O⁺) in solution, i.e., to set the correct pH for the drug product. U.S. Food and Drug Administration
  • In parenteral/ophthalmic/otic formulations, pH adjusters are often added “q.s.” (quantum satis, “as much or as little as necessary”) to achieve a specified pH or pH range. U.S. Food and Drug Administration
  • The adjuster may also become part of the buffer system (i.e., indistinguishable from buffer components) or may interact to form salts etc. Thus, the role of pH adjusters is somewhat special compared to “fixed” inert ingredients. U.S. Food and Drug Administration

Q1 / Q2 Differences May Be Acceptable

  • Because of the above, the FDA’s current thinking is that in certain circumstances, a Q1 (qualitative) or Q2 (quantitative) difference in a pH adjuster in the generic vs the RLD may be acceptable via waiver under § 314.99(b). U.S. Food and Drug Administration
  • For example:
    • If the RLD uses a pH adjuster listed as “and/or” another adjuster, or uses q.s., meaning batch-to-batch variation in amount. U.S. Food and Drug Administration
    • If the generic applicant can demonstrate that any difference does not change the final product attributes (pH, osmolality, viscosity, etc.) in an unacceptable way. U.S. Food and Drug Administration
  • The guidance notes, however, that this is fact-specific: some differences will not be acceptable (for example, if a different pH adjuster leads to a new counter-ion species or salt not present in the RLD, or introduces a novel inactive ingredient without known safety profile). U.S. Food and Drug Administration

Factors/Information FDA May Consider When Evaluating a Waiver Request

The guidance recommends that an ANDA applicant seeking a waiver provide the following types of information:

  • Comparative physicochemical characterization between proposed product and RLD: pH, buffer capacity, osmolality, viscosity, electrophoretic mobility, concentration of pH adjuster and any resulting salts/free acid/base species. U.S. Food and Drug Administration+1
  • Safety justification of the proposed pH adjuster difference: e.g., demonstration that the pH adjuster (or its counter-ion) has been used in previously FDA-approved drug products for the same route; appropriate exposure amounts; reference to the Inactive Ingredients Database (IID). U.S. Food and Drug Administration
  • Demonstration that the difference in pH adjuster does not meaningfully affect bioequivalence (BE), or key product quality attributes which may influence efficacy or safety. U.S. Food and Drug Administration
  • The extent and type of information may vary depending on dosage form complexity: for solutions, fewer data may suffice; for suspensions, gels, emulsions, more data may be required. U.S. Food and Drug Administration

Timing and Process for Submission of Waiver Request

  • The applicant is encouraged to submit a controlled correspondence or pre-ANDA meeting request to the FDA during development to get a formulation assessment comparing the proposed generic and the RLD. U.S. Food and Drug Administration+1
  • If the controlled correspondence indicates that the formulation does not meet the inactive ingredient requirement due to a pH adjuster difference, the applicant may consider including a § 314.99(b) waiver request. U.S. Food and Drug Administration
  • If the applicant chooses not to use the controlled correspondence route, then a waiver request must be included in the ANDA submission if the generic has a Q1/Q2 difference in pH adjuster vs the RLD. The FDA will refuse to receive an ANDA that has a Q1/Q2 difference in pH adjuster without a § 314.99(b) waiver request. U.S. Food and Drug Administration
  • The ANDA cover letter (Module 1 of the eCTD) should clearly indicate that a waiver request is included. The waiver request should be located in the Module/Section/Sub-section where otherwise the regulatory requirement is addressed. U.S. Food and Drug Administration
  • Outcome: FDA can grant a waiver if it finds compliance unnecessary, or alternative submission satisfies the requirement, or other justification is provided. The decision is communicated when FDA acts on the ANDA (approval, complete-response, or refuse-to-receive). U.S. Food and Drug Administration
  • If a waiver is granted, note: the generic with a pH adjuster difference would not be eligible under 21 CFR 320.22(b)(1) for an in-vivo BE waiver simply because of same inactive ingredients; additional BE considerations apply. U.S. Food and Drug Administration

Implications & Key Take-aways

For generic drug applicants in the parenteral/ophthalmic/otic space, this guidance offers clarity on an area that has seen questions: modifications to pH adjusters. Key implications include:

  • Greater flexibility: This guidance signals that the FDA is open to pH adjuster differences (qualitative or quantitative) provided scientifically justified and documented — which may facilitate generics development when the RLD uses “q.s.” or variable amounts of adjuster.
  • Need for strong characterization: The burden is on the applicant to demonstrate that any difference does not affect product performance, stability, safety or BE. Emphasis on physicochemical comparability and safety justification.
  • Regulatory strategy: Early engagement with FDA (via controlled correspondence or pre-ANDA meeting) is encouraged when a pH adjuster difference is likely. Failing to submit a requested waiver when required means the ANDA may be refused to be received.
  • Risk of in-vivo BE implications: Even if a waiver is granted for the pH adjuster difference, the applicant must consider whether the generic is still eligible for certain BE shortcuts; if not, additional BE data may be needed.
  • Narrow scope: This applies only to pH adjusters in parenteral/ophthalmic/otic generic products. Other inactive ingredients or other dosage forms remain subject to more stringent “same inactive in same concentration” unless exception-excipient justification is provided.
  • International relevance: For global generics and pharmaceutical regulatory affairs professionals (such as in India), the guidance provides insight into how the FDA is interpreting Q1/Q2 differences for critical inactive ingredients and may influence reference strategies for ANDAs to US markets or discussions with global regulators.

Specific Considerations for Indian/Global Generic Industry (and for regulatory affairs professionals)

Since you (as a regulatory affairs consultant and pharmaceutical industry professional) are engaged in regulatory affairs and generics, some tailored observations:

  • When preparing ANDAs for the U.S., ensure any pH adjuster differences are identified early (e.g., formulation stage) so you can engage with FDA via controlled correspondence and prepare the waiver justification—as opposed to discovering a difference late and risking refusal to receive.
  • If the RLD formulation lists a pH adjuster as “q.s.”, this may provide a more favourable context for your argument of variability being acceptable. You’ll need data on batch-to-batch variation, final pH, buffer capacity etc.
  • For generics manufactured in India and exported to U.S., the dossier should include robust physicochemical comparability (pH, buffer capacity, osmolality, viscosity, etc). Ensure the local Indian manufacturing control strategy supports these data.
  • Remember: Any qualitative change (type of pH adjuster) yields greater regulatory scrutiny. Provide precedents (ingredient used in other FDA-approved products), safety exposure data, and ensure counter-ion species are not novel/unapproved.
  • For marketing in India or elsewhere, while this FDA guidance may not be directly binding, many regulators in emerging markets often look to FDA guidances for best practice. Thus, aligning your formulation development/regulatory strategy with this standard may strengthen global credibility.
  • From a business strategy standpoint: When consulting for generics, you can highlight to clients/manufacturers that the FDA is willing to accept scientifically-justified modifications of pH adjusters—this may allow faster time-to-market for generic versions of complex parenteral/ophthalmic/otic products, provided the waiver strategy is well-planned.

Article Summary

In sum, the FDA’s November 2025 guidance on pH adjuster waiver requests provides a considered framework for when ANDA applicants of generic parenteral/ophthalmic/otic products can request flexibility on pH adjusters (both qualitative and quantitative) via §314.99(b). It emphasises:

  • The special role of pH adjusters in those dosage forms (often q.s., variable, interacting with buffers)
  • That in certain circumstances a difference may be acceptable if justified by data
  • The types of information FDA may consider (physicochemical, safety, BE)
  • Process and timing for requesting a waiver (controlled correspondence/pre-ANDA meeting, ANDA submission, waiver request format)
  • Implications (both opportunities and risks) for generic developers and regulatory affairs professionals

For companies in generics development and regulatory consulting (such as your consulting services for pharma companies), this guidance underscores the importance of early formulation assessment, rigorous comparability data, and proactive discussions with FDA when pH adjuster differences arise.

Discover more from सुदर्शन

Subscribe to get the latest posts sent to your email.

error: Content is protected !!